53 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
the information contained in such sources. Table of Contents iii
SUMMARY OF RISK FACTORS Our ability to implement our business strategy is subject to numerous … on oncology and our partnership strategy allows us to explore other indications. Our full pipeline, including partnerships, is reflected in the image below
8-K
EX-99.1
afid mot8611ta
11 Jan 24
Regulation FD Disclosure
7:05am
8-K
EX-99.1
cfn36h 0z5d1ywc
12 Dec 23
Regulation FD Disclosure
4:28pm
8-K
EX-99.1
e7fkpm
1 Nov 23
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7:18am
8-K
EX-99.1
rpe2t8
5 Sep 23
C4 Therapeutics Announces Chief Financial Officer Succession
4:02pm
8-K
EX-99.1
ceq7389f
20 Jun 23
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
7:11am
8-K
EX-10.1
wf0bea hnu
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
rhrp25b
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
qtueqegi
18 Apr 23
Preliminary proxy
7:59am
8-K
EX-99.1
4ac fbg56
4 Aug 22
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:15am